Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOSNASDAQ:MRSNNASDAQ:ORMPOTCMKTS:TRXDW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Therapeutics$0.82+1.8%$0.71$0.55▼$1.71$106.49M1.01795,814 shs507,214 shsMRSNMersana Therapeutics$0.32-4.8%$0.38$0.26▼$2.88$39.75M1.322.51 million shs1.95 million shsORMPOramed Pharmaceuticals$2.25-1.7%$2.27$1.82▼$3.09$91.91M1.65154,452 shs57,635 shsTRXDWTransEnterix$0.15$0.15$0.12▼$0.18$21.42M2.568,250 shsN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Therapeutics0.00%-3.62%+39.80%+7.71%-50.93%MRSNMersana Therapeutics0.00%-19.81%+22.00%-57.48%-90.62%ORMPOramed Pharmaceuticals0.00%-3.02%+5.63%+3.69%-7.41%TRXDWTransEnterix0.00%0.00%0.00%0.00%+13,536.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Therapeutics1.7914 of 5 stars3.52.00.00.02.21.70.0MRSNMersana Therapeutics3.8189 of 5 stars3.52.00.04.12.62.50.0ORMPOramed Pharmaceuticals1.1215 of 5 stars0.03.00.00.01.90.81.9TRXDWTransEnterixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Therapeutics 3.00Buy$7.13764.26% UpsideMRSNMersana Therapeutics 3.00Buy$3.671,049.79% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ATRXDWTransEnterix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRXDW, ATOS, ORMP, and MRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00 ➝ $3.004/21/2025ATOSAtossa TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.253/26/2025ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/12/2025ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/3/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00(Data available from 5/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/AMRSNMersana Therapeutics$40.50M0.98N/AN/A$0.31 per share1.03ORMPOramed Pharmaceuticals$1.34M68.59N/AN/A$4.04 per share0.56TRXDWTransEnterix$8.53M2.51$0.11 per share1.40$2.68 per share0.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Therapeutics-$30.09M-$0.21N/AN/AN/AN/A-35.74%-33.51%5/12/2025 (Estimated)MRSNMersana Therapeutics-$171.67M-$0.56N/AN/AN/A-214.20%-401.37%-38.61%N/AORMPOramed Pharmaceuticals$5.53M-$0.2120.45N/AN/AN/A-7.27%-6.20%N/ATRXDWTransEnterix-$154.20M-$4.22N/AN/AN/A-2,149.15%-83.74%-64.94%N/ALatest TRXDW, ATOS, ORMP, and MRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025ATOSAtossa Therapeutics-$0.06N/AN/AN/AN/AN/A3/27/2025Q4 2024ORMPOramed Pharmaceuticals-$0.03$0.01+$0.04$0.01N/AN/A3/25/2025Q4 2024ATOSAtossa Therapeutics-$0.0633-$0.05+$0.0133-$0.05N/AN/A3/3/2025Q4 2024MRSNMersana Therapeutics-$0.16-$0.11+$0.05-$0.11$7.71 million$16.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa TherapeuticsN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ATRXDWTransEnterixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa TherapeuticsN/A13.3013.30MRSNMersana Therapeutics13.352.352.35ORMPOramed PharmaceuticalsN/A27.0827.08TRXDWTransEnterix0.043.242.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Therapeutics12.74%MRSNMersana Therapeutics93.92%ORMPOramed Pharmaceuticals12.73%TRXDWTransEnterix8.22%Insider OwnershipCompanyInsider OwnershipATOSAtossa Therapeutics8.70%MRSNMersana Therapeutics11.80%ORMPOramed Pharmaceuticals13.70%TRXDWTransEnterix3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Therapeutics8129.17 million116.24 millionOptionableMRSNMersana Therapeutics150124.63 million108.96 millionOptionableORMPOramed Pharmaceuticals1040.85 million34.79 millionOptionableTRXDWTransEnterixN/A142.78 millionN/ANot OptionableTRXDW, ATOS, ORMP, and MRSN HeadlinesRecent News About These CompaniesLife Science Partners L P Synergy's Net WorthFebruary 9, 2024 | benzinga.comAsensus Surgical Inc (ASXC)January 30, 2024 | investing.comTransEnterix, Inc. (TRXDW)January 21, 2024 | ca.finance.yahoo.comSurgical Robots Global Market Report 2023June 13, 2023 | finance.yahoo.comAsensus Surgical (NYSEMKT: ASXC)May 27, 2023 | fool.comProfitable Strategic Report for the Robotic Endoscopy Devices Market with Business Strategies, Current Insight - openPRMay 12, 2023 | news.google.comAsia Pacific Minimally Invasive Gastrointestinal (GI) Surgical ... - Cottonwood Holladay JournalMay 12, 2023 | news.google.comGlobal Minimally Invasive Gastrointestinal (GI) Surgical Systems ... - Cottonwood Holladay JournalMay 12, 2023 | news.google.comAsensus Surgical, Inc. Reports Operating and Financial Results for ... - BenzingaMay 12, 2023 | news.google.comSurgical Robots Market 2023 is Booming Across the Globe by ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comBariatric Surgery Devices Market Size, Trends, Share, Growth and ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comSurgical Robots Market: The global market is expected to grow at a ... - Digital JournalMay 10, 2023 | news.google.comMinimally Invasive Gastrointestinal (GI) Surgical Systems Market ... - Digital JournalMay 10, 2023 | news.google.comSurgical Robots Market to Grow at Rapid Pace with Advancements ... - Digital JournalMay 10, 2023 | news.google.comMedical Intelligent Auxiliary Robot Market 2023 Competitive Insights ... - Cottonwood Holladay JournalMay 10, 2023 | news.google.comGlobal Healthcare Robotics-Surgical Robots Market 2023, CAGR ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comSurgical Robots Market Excellent CAGR of 18%, Growth, Industry ... - Digital JournalMay 8, 2023 | news.google.comExponential Growth Expected for Intelligent Tissue Autonomous Robots Market With Complete SWOT Analysis by For - openPRMay 8, 2023 | news.google.comObesity Surgery Device Market Research Report 2023-2031 Market ... - The Northwestern ExaminerMay 7, 2023 | news.google.comGlobal Surgical Robotics Market Insights Report 2022, Trends ... - FylladeyMay 5, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRXDW, ATOS, ORMP, and MRSN Company DescriptionsAtossa Therapeutics NASDAQ:ATOS$0.82 +0.01 (+1.80%) As of 05/9/2025 03:59 PM EasternAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Mersana Therapeutics NASDAQ:MRSN$0.32 -0.02 (-4.81%) As of 05/9/2025 04:00 PM EasternMersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Oramed Pharmaceuticals NASDAQ:ORMP$2.25 -0.04 (-1.75%) As of 05/9/2025 04:00 PM EasternOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.TransEnterix OTCMKTS:TRXDW$0.15 0.00 (0.00%) As of 03/7/2025TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock Constellation Powers Up With Reinforced AI Data Center Strategy GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
